Last reviewed · How we verify
NCT03766763
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A
Phase 2 trial testing Venetoclax in Chronic Lymphoid Leukemia in 82 participants. Participants enrolled and being followed up; not accepting new ones.
1 January 2022
Quick facts
| Lead sponsor | French Innovative Leukemia Organisation |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 82 |
| Start date | 22 May 2019 |
| Primary completion | 1 January 2022 |
| Estimated completion | 24 April 2030 |
| Sites | 23 locations across France |
Drugs / interventions tested
- Venetoclax (venetoclax) — full drug profile →
Conditions studied
- Chronic Lymphoid Leukemia — all drugs for Chronic Lymphoid Leukemia →
Sponsor
French Innovative Leukemia Organisation — full company profile →
Who can join
18 and older, any sex, with Chronic Lymphoid Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Open label, single arm, multicenter phase II trial.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Precision Medicine Management of Chronic Lymphocytic Leukemia.
Moia R, Patriarca A, Schipani M, Ferri V, et al · · 2020 · cited 27× · PMID 32164276 · DOI 10.3390/cancers12030642 -
Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs.
Urso A, Martino EA, Cuneo A, Gentile M, et al · · 2024 · cited 5× · PMID 39123460 · DOI 10.3390/cancers16152732
Verify or expand the search:
- PubMed search for NCT03766763
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Venetoclax
Trials testing the same drug.
- NCT07425808 — FLT3-ITD Targeted Therapy in Fit AML Patients · Phase 2, PHASE3 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
- NCT07175415 — HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological · Phase 1, PHASE2 · not yet recruiting
- NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
- NCT07511062 — Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML · Phase 1 · not yet recruiting
Other recruiting trials for Chronic Lymphoid Leukemia
Currently open trials in the same condition.
- NCT03852407 — Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-inten · Phase 2 · recruiting
Other French Innovative Leukemia Organisation trials
Trials by the same sponsor.
- NCT06547866 — Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated f · Phase 2 · not yet recruiting
- NCT07007052 — Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Bl · Phase 2 · not yet recruiting
- NCT06377579 — OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia · recruiting
- NCT06263387 — Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible · recruiting
- NCT06186648 — Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter S · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03766763 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by French Innovative Leukemia Organisation
- Last refreshed: 26 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03766763.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing